Measles, Mumps and Rubella (MMR) Vaccines Market is Segmented By Type (MMR, MMRV, Others), By End-User (Hospitals, Vaccination Centre, Clinics, Others) and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Measles, Mumps, and Rubella (MMR) Vaccines Market is estimated to reach high CAGR during the forecast period 2024-2031
The MMR vaccine protects against measles, mumps, and rubella. The first dose is usually given to children between the ages of 9 and 15 months, and the second dose is usually given to children between the ages of 15 and 6 years, with at least 4 weeks between doses.
Measles, Mumps and Rubella (MMR) Vaccines Market
| Metrics | Details |
| Market CAGR | Measles, Mumps, and Rubella (MMR) Vaccines Market is estimated to reach high CAGR during the forecast period (2022-2029). |
| Segments Covered | By Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Measles, Mumps and Rubella (MMR) Vaccines Market Dynamics
The factors driving the global measles, mumps, and rubella (MMR) vaccines are the increasing demand for vaccine and vaccination programs by the government is expected to drive the market growth.
The increasing demand for vaccine and vaccination programs by the government is expected to drive market growth in the forecast period
Vaccine manufacturers are collaborating with organizations such as WHO, UNICEF, and the GAVI Alliance to improve their vaccination programs to reach the greatest number of people with vaccines. Despite several government initiatives, measles remains a leading cause of death among children under five. As a result, increasing the success rate of vaccination programs is dependent on each country's government initiatives. In order to reduce the prevalence of these diseases, some organizations are focusing on initiatives. GAVI Alliances, for instance, has launched a vaccination campaign in high-risk countries such as Afghanistan, Chad, Ethiopia, the Democratic Republic of the Congo, Nigeria, and Pakistan.
Similarly, in 2017, the Government of India launched a Pan-India Measles-Rubella vaccination campaign in which children aged 9 months to 15 years are vaccinated in order to reduce the prevalence of these diseases in children. Such initiatives by various organizations and governments are expected to drive market growth.
The side effects associated with vaccination is expected to hamper the market growth
MMR vaccination can result in a sore arm from the injection or redness where the shot is given, fever, and a mild rash. Swelling of the glands in the cheeks or neck and temporary pain and stiffness in the joints (mostly in adolescent or adult women) can occur following MMR vaccination. Serious reactions are uncommon. These can include seizures (frequently associated with fever) or a temporary low platelet count, resulting in unusual bleeding or bruising. This vaccine may cause a potentially fatal infection in people with compromised immune systems. People who have severe immune system problems should not receive the MMR vaccine.
COVID-19 Impact Analysis
During the COVID-19 pandemic, national and international health agencies advised that immunization services be maintained indefinitely due to the possibility of a resurgence of vaccine-preventable diseases, either controlled or eliminated, as a result of low vaccination coverage. However, studies have shown that, in an attempt to reduce the risk of transmission of SARS-CoV-2, the etiological agent of COVID-19, social isolation measures have reduced vaccination programs in children and adolescents in several countries and regions around the world.
For instance, the MMR vaccine, made from live attenuated measles, rubella, and mumps viruses, is free in Brazil and is recommended for routine vaccination at 12 months and 9 years of age. The historical decrease in MMR vaccine coverage rates in Brazil may have been hampered by sanitary measures implemented in response to the COVID-19 pandemic, the distribution of health services, and the allocation of health resources in Brazil affected by COVID-19.
Measles, Mumps and Rubella (MMR) Vaccines Market Segment Analysis
MMR II (measles, mumps, and rubella virus vaccine live) segment is expected to dominate the market growth in the forecast period
M-M-R II is a combination vaccine protecting against measles, mumps, and rubella (MMR). M-M-R II is a sterile lyophilized preparation of ATTENUVAX (Measles Virus Vaccine Live), a more attenuated line of measles virus derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; MUMPSVAX (Mumps Virus Vaccine Live), the Jeryl Lynn (B level) strain of mumps virus propagated in a chick.
Furthermore, M-M-R II comprises weakened strains of live measles, mumps, and rubella viruses. These live virus strains cause either mild or no symptoms of infection. The body responds by producing disease-fighting substances (antibodies) against these infections when the vaccine is given. When a vaccinated child comes into contact with the measles, mumps, or rubella virus, the body is usually ready to destroy it and produces antibodies. However, as with all vaccines, there is no guarantee of complete protection against measles, mumps, and rubella. Furthermore, maximum protection may take up to 4-6 weeks to develop so that infections may occur during this time.
Global Measles, Mumps and Rubella (MMR) Vaccines Market- Geographical Analysis
North America region is expected to hold the largest market share in the global measles, mumps, and rubella (MMR) vaccines market
The growing prevalence of measles, mumps, and rubella and the increasing government vaccination programs in this region are expected to drive the market growth.
In the United States, 371 cases of measles were confirmed in 2018. The Centers for Disease Control and Prevention (CDC) confirmed 1215 cases across 30 states from January to August 2019. In conjunction with mass immunization campaigns in countries with high case and death rates, routine measles vaccination for children is a critical public health strategy for reducing global measles deaths. For nearly 60 years, the measles vaccine has been in use. It is risk-free, efficient, and inexpensive. A child's immunization against measles costs about one dollar in the United States. The availability of vaccines in this region is expected to boost market growth. For instance, in the United States, two vaccines containing the measles, mumps, and rubella virus are approved for use. The M-M-R II vaccine protects against measles, mumps, and rubella (MMR). ProQuad is a vaccine that protects against measles, mumps, rubella, and varicella (MMRV)
Measles, mumps, and rubella (MMR) vaccines market are moderately competitive, increasing company collaborations, clinical trials, acquisitions, and product launches. Some of the key players in the market are GlaxoSmithKline plc, Merck & Co. Inc. and Serum Institute of India Ltd, Daiichi Sankyo Company, Limited, Takeda Pharmaceutical Company Limited.
GlaxoSmithKline plc
Overview: GlaxoSmithKline is a science-led global healthcare company. It is the world’s largest vaccines company by revenue, delivering vaccines that help protect people at all stages of life. GlaxoSmithKline pharmaceuticals have a broad portfolio of innovative and established HIV, respiratory, immuno-inflammation, and oncology medicines. The company was founded in 2000.
Product Portfolio: Priorix is a lyophilized mixture of the attenuated viruses Schwarz measles, RIT 4385 mumps (derived from the Jeryl Lynn strain), and Wistar RA 27/3 rubella. The vaccine's measles and mumps components are made in chick embryo cell culture and may contain traces of egg protein. It is indicated to protect against measles, mumps, and rubella.
Key Developments: On August 2nd, 2021, GlaxoSmithKline submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for its Priorix vaccine, seeking approval for use in active immunization against measles, mumps, and rubella infection (MMR). If approved, the Priorrix vaccine would provide an alternative MMR vaccine to healthcare providers in the United States.
Frequently Asked Questions
What is the Projected CAGR value of the Measles, Mumps and Rubella (MMR) Vaccines Market?
Measles, Mumps, and Rubella (MMR) Vaccines Market is estimated to reach high CAGR during the forecast period (2022-2029).
Which region controlled the global market during 2022-2029?
North America region Controls the Measles, Mumps and Rubella (MMR) Vaccines Market during 2022-2029
Which is the fastest growing region in the Measles, Mumps and Rubella (MMR) Vaccines Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period
